Secondary analysis of the JADE MOA trial (43 patients analysed) in moderate-to-severe atopic dermatitis: abrocitinib 100 or 200 mg vs placebo for 12 weeks dose-dependently reduced Staphylococcus and S. aureus abundance; diversity rose at Week 12 with 200 mg.
Secondary analysisn = 43
Kim et al. Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis